Track the 유바이오로직스 stock price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are quoted on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 유바이오로직스 has logged 74 insider filings. Market capitalisation: €290.8bn. The latest transaction was disclosed on 3 April 2026 (Purchase). Among the most active insiders: 바이오노트. The full history is openly available.
74
Insider Decl.
n/a
Thresholds
n/a
64 ops.
Buy Volume
n/a
1 ops.
Sell Volume
9Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 214 of 29,062 companies
88.4
score / 100
Value
90
Quality
87
FCF yld11%
Earn yld14%
EV/EBITDA4.6x
ROE·
Gross mgn58%
Net mgn28%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.